A $707 million investment in cell-based influenza vaccine

The United States has provided a large sum of money to pharmaceutical giant Novartis to produce influenza vaccines grown in cell culture. According to CIDRAP: Novartis’s US efforts have been spurred by two major federal contracts. In 2006 the firm won a $220 million HHS contract to develop cell-based flu vaccines, and in January 2009 …

A $707 million investment in cell-based influenza vaccine Read More »